Author: Elion Medical Communications

Industry Insights: MedComms 24 October

Industry Insights MedComms

In this piece, we spotlight three issues in the publishing world that are driving conversations within the industry. We look at inaccurate author disclosures in medical publishing, delve into the open access debate, and discuss the art of crafting suitable lay titles for clinical trials. The problem of unreliable author disclosures persists in the medical […]

Industry Insights: AI 12 October

Industry Insight: AI

This Insight focuses on: 1) the Healthcare Communication Association’s position paper on AI, 2) six principles that can help you start using AI for communications, and 3) the value of the AI market in medical writing. The Healthcare Communications Association (HCA) has published a position paper on AI in Current Medical Research and Opinion. The […]

Industry Insights: MedComms 2 October

Industry Insights MedComms

Here we cover three hot topics in publishing that are shaping the industry dialogue. We focus on BioGPT: a generative AI model that generates fluent descriptions for biomedical terms, why there is a call to reform the current scholarly publishing model, and using the patient voice in publishing. As generative AI models like BioGPT and […]

Threats and opportunities of mega journals

Creative World Book Day Composition

What is the impact of large journals that regularly publish thousands of articles per year? Does it have any impact on the overall quality of research being published? Does it help advance the availability and publication of research? Journals that regularly publish thousands of articles are termed mega journals. Mega journals can be characterised by […]

Industry Insights: Healthcare 25 September

Industry Insight: Healthcare

This week our industry insights look at news highlighting the importance of full disclosure in the promotion of medicines, EU recommendation for the approval of an antibody-drug for the treatment of NSCLC, and a popular oral decongestant that could be removed from the US market. Novartis has been found to have seriously breached the ABPI […]

Industry Insights: MedComms 18 September

Industry Insights MedComms

With the ongoing pressure in the academic world to publish, the term ‘Publish or Perish’ is well known. Here we cover three important and related topics in the industry. We look at the use of embellished language (hyperbolic adjectives) in scientific writing, and publishing in predatory as well as open access (OA) journals.  In recent […]

Industry Insights: Healthcare 11 September

Industry Insight: Healthcare

This week, our industry news insights looks at an announcement of a new phase III trial for non-small cell lung cancer, artificial intelligence (AI) for breast cancer detection, and dramatic increases in cancer rates for under-50s. Taiho Oncology and Cullian Oncology have announced the phase III trial of zipalertinib in EGFR exon 20 insertion mutation […]

Industry Insights: MedComms 4th of September

Industry Insights MedComms

Here we examine three hot topics in medical writing that are shaping the industry dialogue. We take a look at the impact of retracted scientific articles, the advantages of using artificial intelligence (AI) in text creation, and the ban by Nature on the use of AI-generated visual content in its journals. There is increasing concern […]

Industry insights: Healthcare 28th of August

Industry Insight: Healthcare

Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week take a look at new US Government funding into vaccines and therapies for COVID and FDA clearance for new AI technology to help spot lung nodules. We also explore the impact of Keytruda (pembrolizumab) in […]

Industry Insights: Healthcare 14 August

Industry Insight: Healthcare

Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week our industry insights look at news highlighting how artificial intelligence (AI) could be used for cancers of unknown primary origin, further findings from a Novo Nordisk’s Wegovy trial, and a new novel oral treatment for […]

Industry insights: Healthcare 1st of August

Industry Insight: Healthcare

Obesity and rheumatological conditions are an area of Elion’s expertise. This week our industry news insights look at the correlation between obesity and psoriasis, findings from a trial of a promising treatment for Alzheimer’s, and the initiation of Phase III study involving Merck’s Keytruda. It is well established that obesity is a risk factor for […]